A Human Influenza Transmission Study Using Naturally Infected Community Donors (FLU-TIDE)

FLU-TIDE: A Controlled Human Influenza Transmission Study Using Naturally Infected Community Donors

The purpose of this study is to determine whether influenza A or B can be transmitted from adults with naturally acquired community influenza infection to healthy adult recipients under controlled inpatient exposure conditions, and to identify donor, recipient, viral, immunologic, behavioral, and environmental factors associated with transmission.

This study differs from a traditional influenza CHIM because no challenge stock will be administered. Instead, naturally infected community donors will serve as the source of exposure. This approach is intended to better reflect naturally circulating influenza viruses and naturally infected donors while preserving the safety advantages of inpatient monitoring, defined exposure windows, controlled environmental measurements, and standardized sampling.

Study Overview

• Status: Not yet recruiting
• Conditions: Influenza
• Intervention / Treatment: Other: Influenza Donor Visit; Other: Influenza Recipient Inpatient Exposures Sessions

Detailed Description

Influenza remains a major cause of respiratory illness, hospitalization, and death worldwide. Seasonal influenza vaccines and antivirals are available, though vaccine effectiveness varies by season and by match between vaccine and circulating strains, and antivirals are most effective when administered early. Improved methods are needed to understand how influenza transmits between humans and to identify donor, recipient, viral, immune, and environmental factors that influence transmission.

Controlled human infection models (CHIM) for influenza have provided important information about influenza pathogenesis, clinical illness, viral shedding, immune responses, and safety in healthy adults. The Emory influenza CHIM protocol established an operational model in which healthy adults are screened, admitted to the Emory University Hospital challenge unit, challenged and monitored with daily clinical assessments and polymerase chain reaction (PCR) testing, and followed after discharge. That model also includes natural-exposure procedures in which exposed participants spend defined periods in an enclosed setting with structured activities, CO₂ monitoring, and environmental measurements. However, traditional CHIM studies administer a standardized challenge stock, which may not fully represent the transmission biology of currently circulating community influenza viruses.

The proposed study addresses this gap by using adults with naturally acquired community influenza A or B infection as donors. These donors will not be experimentally infected by the study. Instead, donors will be identified rapidly from the community, tested by rapid antigen and/or PCR, and brought to the controlled exposure unit for same-day donor visits. Healthy adult recipients will be admitted to the Emory University Hospital challenge unit and may be exposed to one or more naturally infected donors over multiple exposure days. This design preserves the controlled monitoring and safety infrastructure of a CHIM while more closely modeling transmission from naturally infected persons.

The present protocol incorporates those lessons by enriching for donors with cough and recent symptom onset, excluding recipients who received the current-season influenza vaccine, allowing multiple donors and multiple exposure days, enrolling recipients 18-49 years old, and the utilization of specialized exposure chambers allowing the control of different environmental factors.

The study will also use a Modular Influenza Sampling Tunnel (MIST) and related bioaerosol sampling approaches to characterize donor source strength. The MIST platform allows infectious influenza in expelled respiratory particles to be captured on cell monolayers during activities such as speaking, singing, coughing, and sneezing.

No investigational influenza virus, investigational drug, or investigational biologic will be administered in this protocol.

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nadine Rouphael, MD, MSc; Phone Number: 404-712-1435; Email: nroupha@emory.edu

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Hope Clinic
    • Atlanta, Georgia, United States, 30322
      • Emory University Hospital (EUH)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Recipient Inclusion Criteria:

1. Provide written informed consent before initiation of any study procedures.
2. Are able to understand and comply with all planned study procedures, including inpatient quarantine, donor-exposure sessions, infection-control procedures, symptom reporting, specimen collection, and follow-up.
3. Healthy adults aged ≥18 and ≤49 years at the time of first donor exposure.
4. Participants who can become pregnant must be practicing abstinence or using an acceptable method of contraception for at least 30 days before first donor exposure and through Day 91. A participant is considered not of childbearing potential if post-menopausal or surgically sterilized.
5. Participants who can become pregnant must have a negative serum or urine pregnancy test at screening and a negative urine pregnancy test within 24 hours before first donor exposure.

6. Are in good general health, as determined by the PI or designee, and do not have medical conditions that increase risk for influenza complications, including but not limited to:

   • Chronic pulmonary disease, including asthma or emphysema.
   • Chronic cardiovascular disease, including cardiomyopathy, congestive heart failure, prior cardiac surgery, ischemic heart disease, or known anatomic cardiac defects.
   • Chronic medical conditions requiring close medical follow-up or hospitalization during the past 5 years, including diabetes mellitus, renal dysfunction, or hemoglobinopathies.
   • Immunosuppression, ongoing malignancy, or history of malignancy, excluding non-melanotic skin cancer in remission without treatment for more than 5 years.
   • Neurologic or neurodevelopmental conditions, including cerebral palsy, epilepsy, stroke, or seizures.
   • History of post-infectious or post-vaccine neurologic sequelae.
   • Autoimmune, inflammatory, vasculitic, or rheumatic disease, including but not limited to systemic lupus erythematosus, polymyalgia rheumatica, rheumatoid arthritis, or scleroderma.
7. Demonstrate knowledge and comprehension of the study by scoring ≥70% on a quiz of study procedures, risks, and policies.
8. Agree not to use cigarettes, e-cigarettes, marijuana, or other tobacco products during the quarantine period.
9. Agree not to use prescription or over-the-counter medications that could affect influenza susceptibility, symptoms, viral shedding, or safety assessments, including oseltamivir, zanamivir, peramivir, baloxavir marboxil, amantadine, rimantadine, aspirin, intranasal steroids, acetaminophen, decongestants, antihistamines, and other NSAIDs, within 14 days before first donor exposure and through the quarantine period, unless approved by the PI or designee.

10. Agree to avoid contact with persons at high risk for influenza complications after discharge, as instructed by the study team.

    Recipient Exclusion Criteria:

11. Have household contact with, or daily contact with:

    • Children under 5 years of age.
    • Children or teenagers receiving long-term aspirin therapy.
    • Persons who are pregnant or trying to become pregnant.
    • Persons older than 65 years of age.
    • Persons of any age with significant chronic medical conditions, including chronic pulmonary disease, chronic cardiovascular disease, chronic metabolic disease, renal dysfunction, hemoglobinopathy, immunosuppression, cancer, or neurologic/neurodevelopmental conditions.
12. Are healthcare workers with patient contact during the two weeks after final donor exposure or discharge from quarantine.
13. Plan to live in a confined environment, such as a ship, camp, dormitory, shelter, or other congregate setting, during the two weeks after final donor exposure or discharge from quarantine.
14. Are breastfeeding or plan to breastfeed through Day 91.
15. Have a body mass index less than or equal to 18.5 or greater than or equal to 35.
16. Smoke more than four cigarettes, e-cigarettes, marijuana, or other tobacco products on a weekly basis within 60 days before first donor exposure.
17. Have moderate or severe illness within 7 days before admission or first donor exposure, including but not limited to oral temperature ≥100°F, diarrhea, or vomiting.
18. Had laboratory-confirmed influenza in the current season or influenza-like illness in the current season.
19. Have a pulse rate less than 55 beats per minute or greater than 100 beats per minute. If the pulse rate is <55 beats per minute and the PI or designee determines this is not clinically significant, such as in an athletic participant, and the heart rate increases to >55 beats per minute with moderate exercise, the participant will not be excluded.
20. Have systolic blood pressure less than 90 mmHg or greater than 140 mmHg on two separate measurements.
21. Have diastolic blood pressure less than 50 mmHg or greater than 90 mmHg on two separate measurements.
22. Have long-term use, defined as ≥2 weeks, of high-dose oral glucocorticoids, defined as ≥20 mg per day prednisone or equivalent, parenteral glucocorticoids, or high-dose inhaled steroids for greater than 7 days in the last 3 months.
23. Have active HIV, hepatitis B, or hepatitis C infection.
24. Have screening laboratory test results, including white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin, or platelet count, outside the laboratory-reported normal values and deemed clinically significant by the PI or designee.
25. Have serum creatinine greater than 1.1 times the upper limit of normal.
26. Have alanine transaminase (ALT) greater than 1.1 times the upper limit of normal.
27. Have abnormal findings on screening ECG deemed clinically significant by the PI or designee.
28. Have abnormal findings on chest X-ray, if performed, deemed clinically significant by the PI or designee.
29. Have ongoing drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within 5 years before first donor exposure.
30. Have a positive urine or serum drug screen for cocaine, benzodiazepines, opiates, or metabolites. Positive results for tetrahydrocannabinol (THC) will not be considered exclusionary.
31. Have any medical, psychiatric, occupational, behavioral, or social condition that, in the judgment of the PI or designee, could make it difficult for the participant to comply with the protocol or could increase risk to the participant or others.
32. Have received an experimental product within 30 days before first donor exposure or plan to receive an experimental product at any time during the study.
33. Plan to enroll in another clinical trial that could interfere with study safety assessment or study endpoints during the study period, including studies involving drugs, biologics, devices, vaccines, or other interventions.
34. Plan to donate blood during the course of the study.
35. Have received the current-season influenza vaccine.
36. Have received a live vaccine within 30 days before first donor exposure or plan to receive a live vaccine before Day 31 after exposure.
37. Have received an inactivated vaccine within 14 days before first donor exposure or plan to receive an inactivated vaccine before Day 14 after exposure.
38. Have received parenteral immunoglobulin or blood products within 3 months before first donor exposure or plan to receive parenteral immunoglobulin or blood products during the study.
39. Have known close contact with anyone known to have influenza in the 7 days before screening, admission, or first donor exposure.
40. Have a known history of allergy to anti-influenza drugs required for clinical management under this protocol or allergy to more than two classes of antibiotics.
41. Have any condition that, in the judgment of the PI or designee, is a contraindication to protocol participation, interferes with compliance with study procedures, or impairs the participant's ability to give informed consent.
42. Have influenza A, influenza B, or any non-influenza respiratory pathogen detected by protocol-specified respiratory pathogen testing before donor exposure.

Donor Inclusion Criteria:

1. Provide written informed consent before initiation of any study procedures.
2. Are aged ≥18 years.
3. Tested positive by protocol-specified PCR or rapid antigen test for influenza A or B.
4. Had acute influenza-like illness or respiratory symptoms consistent with influenza within past 72 hours.
5. Symptom onset no longer than 72 hours before donor enrollment.
6. Are willing and able to comply with donor visit procedures, infection-control procedures, specimen collection, MIST or other bioaerosol sampling if performed, and donor-recipient exposure-session procedures.

7. Participants who can become pregnant must have a negative same-day urine pregnancy test before participation in recipient exposure sessions.

   Donor Exclusion Criteria:

8. Have a non-influenza respiratory pathogen detected by multiplex upper respiratory pathogen testing before recipient exposure.
9. Have known active tuberculosis, current evaluation or treatment for tuberculosis, recent close contact with a person with infectious tuberculosis, cough lasting 3 weeks or longer, coughing blood or sputum from deep in the lungs, unexplained weight loss, night sweats, or other concern for active tuberculosis in the judgment of the PI or designee.
10. Have recent epidemiologic risk factors concerning for novel influenza, including close contact within the prior 10 days with sick or dead birds, poultry, livestock, dairy cattle, raw milk or unpasteurized dairy products, known animal influenza outbreaks, or known or suspected human novel influenza infection.
11. Are pregnant or breastfeeding.
12. Are clinically unstable or have clinically significant abnormal vital signs, worsening respiratory symptoms, oxygen saturation concerns, inability to tolerate study procedures, need for urgent medical evaluation, or any other medical concern that, in the judgment of the PI or designee, makes donor participation unsafe.
13. Have any medical, psychiatric, behavioral, occupational, social, or other condition that, in the judgment of the PI or designee, may interfere with completion of study procedures, make donor participation unsafe, or pose additional infectious risk to recipients.
14. Are unable or unwilling to comply with infection-control procedures or facility restrictions, including restrictions on smoking, vaping, marijuana use, or tobacco use while inside the study facility or during study procedures.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Influenza Donors; Adults with naturally acquired community influenza A or B infection are enrolled as donors.These donors are not experimentally infected by the study. Instead, donors are identified rapidly from the community, tested by rapid antigen and/or polymerase chain reaction (PCR), and brought to the controlled exposure unit for same-day donor visits.	Other: Influenza Donor Visit; Donor participants will have screening/testing with a same-day donor visit. The donor visit involves a donor exposure session and/or research sampling prior to discharge from donor visit.If eligible, repeat donor visits are possible. Study staff will monitor exposure sessions and will stop a session for participant safety or donor clinical deterioration.
Experimental: Influenza Recipients; Healthy adult recipients are admitted to the Emory University Hospital challenge unit and intentionally exposed to one or more naturally infected donors under controlled inpatient conditions over multiple exposure days.	Other: Influenza Recipient Inpatient Exposures Sessions; Recipient are admitted to the Emory University Hospital challenge unit in cohorts of 2-10 recipients. Each cohort may be exposed to one or more naturally infected donors over up to 7 donor-exposure days. Exposure sessions may last up to 4 continuous hours and no more than 8 total exposure hours per day. During exposure sessions, donors and recipients may participate in structured social activities such as conversation, reading aloud, singing, games, light group activities, and shared-object activities. Environmental conditions may be collected to help interpret transmission outcomes. Recipients testing negative may be discharged 4 days after last exposure, while those testing positive may be discharged 7 days after the last exposure day before conversion, with discharge delayed if not clinically stable. Outpatient follow-up occurs for up to 91 days with an optional visit at Day 365 for research sampling.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Participants Developing Influenza Infection	Secondary attack rate of laboratory-confirmed influenza infection among exposed recipients, defined as the proportion of healthy adult recipients who develop laboratory-confirmed influenza A or B infection after controlled exposure to one or more naturally infected adult community donors within the quarantine period.	During the quarantine period (up to Day 14)
Number of Recipients Experiencing A Serious Adverse Event	Safety of controlled exposure to naturally infected influenza donors in healthy adult recipients is assessed by the number and proportion of exposed recipients with serious adverse events.	Up to Day 91
Number of Recipients with Severe Influenza Disease	Safety of controlled exposure to naturally infected influenza donors in healthy adult recipients is assessed by the number and proportion of exposed recipients with severe influenza disease. Severe influenza disease is defined as laboratory-confirmed influenza A or B infection plus persistent Grade 3 severity in respiratory rate, tachycardia, blood pressure, oxygen saturation, or temperature not attributed to another cause and sustained for two days; radiologically confirmed pneumonia; organ involvement such as encephalitis or myocarditis; or investigator determination that the clinical syndrome represents severe influenza disease.	Up to Day 91
Number of Recipients Experiencing an Adverse Event	Safety of controlled exposure to naturally infected influenza donors in healthy adult recipients is assessed by the number and proportion of exposed recipients with adverse events.	Up to Day 31

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of Viral Shedding in Recipients	The frequency of influenza viral shedding in recipients following donor exposure within the quarantine period.	During the quarantine period (up to Day 14)
Timing of Viral Shedding in Recipients	The timing of influenza viral shedding in recipients following donor exposure within the quarantine period.	During the quarantine period (up to Day 14)
Duration of Viral Shedding in Recipients	The duration of influenza viral shedding in recipients following donor exposure within the quarantine period.	During the quarantine period (up to Day 14)
Magnitude of Viral Shedding in Recipients	The magnitude of influenza viral shedding in recipients following donor exposure within the quarantine period.	During the quarantine period (up to Day 14)
Number of Symptomatic Recipient Participants	The clinical symptoms and signs of influenza infection are assessed in recipients, including InFLUenza Patient-Reported Outcome (FluPRO) questionnaire responses, duration, nature and severity of symptoms.	During the quarantine period (up to Day 14)
Number of Recipient Participants with Mild to Moderate Influenza	Mild to moderate influenza disease (MMID) is defined as laboratory-confirmed influenza A or B infection plus one or more influenza-associated symptoms or signs judged by the PI or designee to be related to influenza infection.	During the quarantine period (up to Day 14)

Collaborators and Investigators

• Sponsor: Emory University
• Collaborators: National Philanthropic Trust (NPT)
• Investigators: Principal Investigator: Nadine Rouphael, MD, MSc, Emory University

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2026
• Primary Completion (Estimated): March 1, 2031
• Study Completion (Estimated): March 1, 2031

Study Registration Dates

• First Submitted: September 5, 2026
• First Submitted That Met QC Criteria: September 5, 2026
• First Posted (Actual): September 11, 2026

Study Record Updates

• Last Update Posted (Actual): September 11, 2026
• Last Update Submitted That Met QC Criteria: September 5, 2026
• Last Verified: September 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Influenza, Human
• Other Study ID Numbers: 2026P001601

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Deidentified individual participant data that underlie the primary and secondary results reported in peer-reviewed publications, together with associated data dictionaries, will be shared. These data will include recipient laboratory-confirmed influenza infection status, protocol-defined safety outcomes, quantitative polymerase chain reaction (qPCR)-based viral-shedding measurements, and clinical outcomes, including FluPRO scores.
• IPD Sharing Time Frame: Data underlying each publication will become available at the time the corresponding peer-reviewed publication is first made publicly available and will remain available for at least five years thereafter.
• IPD Sharing Access Criteria: Data will be available for sharing with qualified researchers who submit a methodologically sound proposal whose proposed use is scientifically appropriate, feasible, consistent with informed consent, and compatible with applicable privacy, institutional, and regulatory requirements. Data will be shared for purposes of reproducing or validating published analyses, conducting approved analyses, or performing individual-participant-data meta-analyses. Written proposals will be submitted to the FLU-TIDE Principal Investigator and reviewed for scientific merit, methodological soundness, feasibility, consistency with informed consent, and adequacy of privacy protections. Approved requestors will execute an Emory-approved data-use agreement, and data will be provided through a secure Emory-approved data-transfer mechanism. Requestors will be prohibited from attempting to reidentify participants or redistributing the data.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No